Evidence map›Paper›PMID 30586711›Full record

ArticleCirculation2019

LMO7 Is a Negative Feedback Regulator of Transforming Growth Factor β Signaling and Fibrosis.

Yi Xie, Allison C Ostriker, Yu Jin, Haidi Hu, Ashley J Sizer, Gang Peng, Aaron H Morris, Changwan Ryu, Erica L Herzog, Themis Kyriakides and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Integrin Signaling Pathways in Aortic Aneurysm and Dissection.Reviews in cardiovascular medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. The role of inner nuclear membrane protein emerin in myogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  9. Article
  10. Article
  11. CD34Theranostics · 2025
    Article
  12. Article
  13. Role of LMO7 in cancer (Review).Oncology reports · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Yi XieDepartments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Allison C OstrikerDepartments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Yu JinDepartments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Haidi HuSurgery (Vascular) (H.H., A.D.), Yale University, New Haven, CT.
Ashley J Sizer
Gang PengBiostatistics (G.P., H.Z.), Yale University, New Haven, CT.
Aaron H MorrisPathology (A.H.M., T.K.), Yale University, New Haven, CT.
Changwan RyuMedicine (Pulmonary) (C.R., E.L.H.), Yale University School of Medicine, Yale University, New Haven, CT.
Erica L HerzogMedicine (Pulmonary) (C.R., E.L.H.), Yale University School of Medicine, Yale University, New Haven, CT.
Themis KyriakidesPathology (A.H.M., T.K.), Yale University, New Haven, CT.
Hongyu ZhaoBiostatistics (G.P., H.Z.), Yale University, New Haven, CT.
Alan DardikSurgery (Vascular) (H.H., A.D.), Yale University, New Haven, CT.
Jun YuDepartment of Physiology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA (J.Y.).
John HwaDepartments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Kathleen A MartinDepartments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Yale University · USCardiovascular Research Center · BRTemple University · US

Funding

Translational CoreP01DK057751 · NIDDK · YALE UNIVERSITY · PI YANG, XIAOYONG · 2001 to 2020
$25.6M
Pilot Study: POPULATION PHARMACOLOGYU54HL117798 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2016
$18.5M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiationR01HL091013 · NHLBI · YALE UNIVERSITY · PI MARTIN, KATHLEEN ANN · 2008 to 2017
$4.1M
Hyperglycemia, thromboxane and platelet activity in diabetes mellitusR01HL115247 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2012 to 2019
$3.8M
Novel Immunologic Effects of Semaphorin 7a in IPFR01HL109233 · NHLBI · YALE UNIVERSITY · PI HERZOG, ERICA L · 2011 to 2019
$3.7M
Platelet Mitochondrial Function in Health and DiseaseR01HL122815 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2015 to 2023
$3.7M
Pharmacogenetics of the human prostacyclin receptor.R01HL074190 · NHLBI · YALE UNIVERSITY · PI HWA, JOHN · 2004 to 2013
$3.3M
Novel insights into intimal hyperplasia in cardiac allograft vasculopathyR01HL142090 · NHLBI · YALE UNIVERSITY · PI MARTIN, KATHLEEN ANN · 2018 to 2021
$2.4M
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2R01HL146101 · NHLBI · YALE UNIVERSITY · PI GALLAGHER, PATRICK G, MARTIN, KATHLEEN ANN · 2019 to 2022
$2.2M
Molecular control of ischemia-induced tissue fibrosisR01HL153599 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YU, JUN · 2020 to 2023
$2.1M
Enhancing venous adaptation to the arterial environmentR01HL128406 · NHLBI · YALE UNIVERSITY · PI DARDIK, ALAN · 2016 to 2019
$1.9M
NHLBI NIH HHS R01 HL074190NHLBI NIH HHS R01 HL091013NHLBI NIH HHS R01 HL109233NHLBI NIH HHS R01 HL115247NHLBI NIH HHS R01 HL118430NHLBI NIH HHS R01 HL119529NHLBI NIH HHS R01 HL122815NHLBI NIH HHS R01 HL125850NHLBI NIH HHS R01 HL126933NHLBI NIH HHS R01 HL128406NHLBI NIH HHS R01 HL142090NHLBI NIH HHS R01 HL146101NHLBI NIH HHS R01 HL153599NHLBI NIH HHS R56 HL117064NHLBI NIH HHS U54 HL117798NIDDK NIH HHS P01 DK057751NIGMS NIH HHS T32 GM007324
6 · The paper itself

Abstract

backgroundVascular smooth muscle cells (SMCs) synthesize extracellular matrix (ECM) that contributes to tissue remodeling after revascularization interventions. The cytokine transforming growth factor β (TGF-β) is induced on tissue injury and regulates tissue remodeling and wound healing, but dysregulated signaling results in excess ECM deposition and fibrosis. The LIM (Lin11, Isl-1 & Mec-3) domain protein LIM domain only 7 (LMO7) is a TGF-β1 target gene in hepatoma cells, but its role in vascular physiology and fibrosis is unknown.

methodsWe use carotid ligation and femoral artery denudation models in mice with global or inducible smooth muscle-specific deletion of LMO7, and knockout, knockdown, overexpression, and mutagenesis approaches in mouse and human SMC, and human arteriovenous fistula and cardiac allograft vasculopathy samples to assess the role of LMO7 in neointima and fibrosis.

resultsWe demonstrate that LMO7 is induced postinjury and by TGF-β in SMC in vitro. Global or SMC-specific LMO7 deletion enhanced neointimal formation, TGF-β signaling, ECM deposition, and proliferation in vascular injury models. LMO7 loss of function in human and mouse SMC enhanced ECM protein expression at baseline and after TGF-β treatment. TGF-β neutralization or receptor antagonism prevented the exacerbated neointimal formation and ECM synthesis conferred by loss of LMO7. Notably, loss of LMO7 coordinately amplified TGF-β signaling by inducing expression of Tgfb1 mRNA, TGF-β protein, αv and β3 integrins that promote activation of latent TGF-β, and downstream effectors SMAD3 phosphorylation and connective tissue growth factor. Mechanistically, the LMO7 LIM domain interacts with activator protein 1 transcription factor subunits c-FOS and c-JUN and promotes their ubiquitination and degradation, disrupting activator protein 1-dependent TGF-β autoinduction. Importantly, preliminary studies suggest that LMO7 is upregulated in human intimal hyperplastic arteriovenous fistula and cardiac allograft vasculopathy samples, and inversely correlates with SMAD3 phosphorylation in cardiac allograft vasculopathy.

conclusionsLMO7 is induced by TGF-β and serves to limit vascular fibrotic responses through negative feedback regulation of the TGF-β pathway. This mechanism has important implications for intimal hyperplasia, wound healing, and fibrotic diseases.

Indexed as

Vascular RemodelingAnimalsCell ProliferationCells, CulturedDisease Models, AnimalExtracellular MatrixFeedback, PhysiologicalFibrosisHyperplasiaIntegrin alphaVbeta3LIM Domain ProteinsMaleMice, Inbred C57BLMice, KnockoutMuscle, Smooth, VascularMyocytes, Smooth MuscleIntegrin alphaVbeta3LIM Domain ProteinsLMO7 protein, humanLmo7 protein, mouseTgfb1 protein, mouseTranscription Factor AP-1Transcription FactorsTransforming Growth Factor beta1extracellular matrixfibrosissmooth muscletranscription factorstransforming growth factor

Identifiers

PMID30586711
PMCPMC6371979
OpenAlexW2912574495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.